Long-term Treatment With the Ketogenic Diet in Epilepsy
Long-term Treatment With the Ketogenic Diet in Epilepsy and Epilepsy-related Rare Diseases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway
- Oslo University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Treatment with the ketogenic diet at the National Centre for Epilepsy (SSE) for 5 years or more
- Able to travel from The National Centre for Epilepsy - SSE (Sandvika) to Rikshospitalet (Gaustad) to perform procedures to investigate cardiovascular risk factors
- Willing to draw extra blood for research purposes
- Willing to sign informed consent and participate in the study in accordance with the study protocol
- Willing to sign informed consent for blood samples to be included in research biobank at the Department of Neurology, Oslo University Hospital
Exclusion Criteria:
- Non-compliance with the dietary treatment for 6 months or longer or more than once per month
- Not possible to communicate with parents in Norwegian or English without interpreter
- Patient not able to cooperate and lie still for about ten minutes during the carotid ultrasound examination
- Psychiatric/mental illness, alcohol or drug abuse or other factors making it impossible to pursue the study protocol
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiovascular risk after long-term treatment with the ketogenic diet
Time Frame: 2018-2022
|
Color duplex ultrasound
|
2018-2022
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Anette Ramm-Pettersen, MD PhD, Oslo University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Brain Diseases, Metabolic
- Mitochondrial Diseases
- Brain Diseases, Metabolic, Inborn
- Pyruvate Metabolism, Inborn Errors
- Epilepsy
- Pyruvate Dehydrogenase Complex Deficiency Disease
Other Study ID Numbers
Other Study ID Numbers
- 18-14061
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.